Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study
Youssra Allach,Mylene Barry‐Loncq de Jong,Pascal R.D. Clephas,Marco W.F. van Gent,Hans‐Peter Brunner‐La Rocca,Mariusz K. Szymanski,Vokko P. van Halm,M. Louis Handoko,Wouter E.M. Kok,Folkert W. Asselbergs,Roland R.J. van Kimmenade,Olivier C. Manintveld,Nicolas M.D.A. van Mieghem,Saskia L.M.A. Beeres,Michiel Rienstra,Marco C. Post,Loek van Heerebeek,C. Jan Willem Borleffs,Raymond Tukkie,Arend Mosterd,Gerard C.M. Linssen,Ruud F. Spee,Mireille E. Emans,Tom D.J. Smilde,Jan van Ramshorst,Charles J.H.J. Kirchhof,Margriet W. Feenema‐Aardema,Carlos A. da Fonseca,Mieke van den Heuvel,Ronald Hazeleger,J.W. Martijn van Eck,Eric Boersma,Isabella Kardys,Rudolf A. de Boer,Jasper J. Brugts
DOI: https://doi.org/10.1002/ejhf.3303
2024-06-03
European Journal of Heart Failure
Abstract:Design and rationale of the BioMEMS study. QoL, quality of life. Graphical abstract is created with BioRender.com Aims Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance for improved therapy. Congestion, a key factor in HF‐related hospitalizations, further underscores the need for timely interventions. Proactive monitoring of intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities for efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms. Methods The BioMEMS study, a substudy of the MONITOR‐HF trial, proposes a multifaceted approach integrating blood biobank data with traditional and novel HF parameters. Two additional blood samples from 340 active participants in the MONITOR‐HF trial were collected at baseline, 3‐, 6‐, and 12‐month visits and stored for the BioMEMS biobank. The main aims are to identify the relationship between temporal biomarker patterns and PA pressures derived from the CardioMEMS‐HF system, and to identify the biomarker profile(s) associated with the risk of HF events and cardiovascular death. Conclusion Since the prognostic value of single baseline measurements of biomarkers like N‐terminal pro‐B‐type natriuretic peptide is limited, with the BioMEMS study we advocate a dynamic, serial approach to better capture HF progression. We will substantiate this by relating repeated biomarker measurements to PA pressures. This design rationale presents a comprehensive review on cardiac biomarkers in HF, and aims to contribute valuable insights into personalized HF therapy and patient risk assessment, advancing our ability to address the evolving nature of HF effectively.
cardiac & cardiovascular systems